Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea

Next Previous
Trial Profile

Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 29 Dec 2021 Planned End Date changed from 1 Apr 2020 to 1 Dec 2023.
  • 29 Dec 2021 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2023.
  • 25 Sep 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top